{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:52Z","timestamp":1789391692117,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-023-02445-w","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:54:43Z","timestamp":1677153283000},"page":"1867-1883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Deberdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Haladyj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"2445_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71:1524\u20139.","journal-title":"Ann Rheum Dis."},{"key":"2445_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/acr.22039","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:1600\u20137.","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2445_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.","journal-title":"Arthritis Res Ther."},{"key":"2445_CR4","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287\u201393.","journal-title":"Arthritis Rheum."},{"key":"2445_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/09546634.2020.1866741","volume":"32","author":"MD Bruin-Weller","year":"2021","unstructured":"Bruin-Weller MD, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32:164\u201373.","journal-title":"J Dermatolog Treat."},{"key":"2445_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","volume":"131","author":"P Yaghmaie","year":"2013","unstructured":"Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428\u201333.","journal-title":"J Allergy Clin Immunol."},{"key":"2445_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/DER.0000000000000526","volume":"31","author":"Z Ren","year":"2020","unstructured":"Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. Dermatitis. 2020;31:157\u201364.","journal-title":"Dermatitis"},{"key":"2445_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.20887","volume":"186","author":"J Wan","year":"2022","unstructured":"Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Gelfand JM. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study*. Br J Dermatol. 2022;186:664\u201372.","journal-title":"Br J Dermatol."},{"key":"2445_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaci.2016.01.015","volume":"138","author":"YMF Andersen","year":"2016","unstructured":"Andersen YMF, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:310-2.e3.","journal-title":"J Allergy Clin Immunol."},{"key":"2445_CR10","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jaci.2018.11.030","volume":"143","author":"A Ascott","year":"2019","unstructured":"Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol. 2019;143:1821\u20139.","journal-title":"J Allergy Clin Immunol."},{"key":"2445_CR11","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jaci.2020.08.041","volume":"147","author":"H He","year":"2021","unstructured":"He H, Del Duca E, Diaz A, et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. J Allergy Clin Immunol. 2021;147:1369\u201380.","journal-title":"J Allergy Clin Immunol."},{"key":"2445_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s13555-021-00538-4","volume":"11","author":"KJ Meyers","year":"2021","unstructured":"Meyers KJ, Silverberg JI, Rueda MJ, et al. Risk of venous thromboembolism among patients with atopic dermatitis: A cohort study in a US administrative claims database. Dermatol Ther (Heidelb). 2021;11:1041\u201352.","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"2445_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","volume":"157","author":"MC Schneeweiss","year":"2021","unstructured":"Schneeweiss MC, Kim SC, Wyss R, et al. Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases. JAMA Dermatol. 2021;157:805\u201316.","journal-title":"JAMA Dermatol."},{"key":"2445_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00403-020-02099-6","volume":"313","author":"MS Shaheen","year":"2021","unstructured":"Shaheen MS, Silverberg JI. Association of inflammatory skin diseases with venous thromboembolism in US adults. Arch Dermatol Res. 2021;313:281\u20139.","journal-title":"Arch Dermatol Res"},{"key":"2445_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","volume":"19","author":"A Paller","year":"2018","unstructured":"Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821\u201338.","journal-title":"Am J Clin Dermatol"},{"key":"2445_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053137","volume":"12","author":"YMF Andersen","year":"2022","unstructured":"Andersen YMF, Nymand L, DeLozier AM, Burge R, Edson-Heredia E, Egeberg A. Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort. BMJ Open. 2022;12: e053137.","journal-title":"BMJ Open"},{"key":"2445_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee S, Lee H, Lee CH, Lee W-S. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:466-77.e16.","journal-title":"J Am Acad Dermatol."},{"key":"2445_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250216","volume":"16","author":"H Lee","year":"2021","unstructured":"Lee H, Kim YC, Choi JW. Alopecia areata is not a risk factor for heart diseases: a 10-year retrospective cohort study. PLoS ONE. 2021;16: e0250216.","journal-title":"PLoS ONE"},{"key":"2445_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/cam4.1448","volume":"7","author":"C-C Chen","year":"2018","unstructured":"Chen C-C, Chang Y-T, Liu H-N, Chen Y-J. Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study. Cancer Med. 2018;7:2153\u20139.","journal-title":"Cancer Med."},{"key":"2445_CR20","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1038\/s41598-018-28142-1","volume":"8","author":"JH Lee","year":"2018","unstructured":"Lee JH, Song Y, Do Han K, et al. Cancer risk by the subtype of alopecia. Sci Rep. 2018;8:9748.","journal-title":"Sci Rep"},{"key":"2445_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.canep.2016.02.009","volume":"41","author":"A Mostaghimi","year":"2016","unstructured":"Mostaghimi A, Qureshi S, Joyce C, Guo Y, Huang KP. Reduced incidence of skin cancer in patients with alopecia areata: a retrospective cohort study. Cancer Epidemiol. 2016;41:129\u201331.","journal-title":"Cancer Epidemiol"},{"key":"2445_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","volume":"27","author":"D Khanna","year":"2004","unstructured":"Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-\u03b1 antagonists. Drug Saf. 2004;27:307\u201324.","journal-title":"Drug Saf"},{"key":"2445_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"J-F Colombel","year":"2004","unstructured":"Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19\u201331.","journal-title":"Gastroenterology"},{"key":"2445_CR24","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ G\u00f3mez-Reino","year":"2003","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122\u20137.","journal-title":"Arthritis Rheum"},{"key":"2445_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76:504\u201310.","journal-title":"Ann Rheum Dis"},{"key":"2445_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72:31\u201340.","journal-title":"Arthritis Rheumatol"},{"key":"2445_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"2445_CR28","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39:4910\u201360.","journal-title":"Adv Ther"},{"key":"2445_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81:335\u201343.","journal-title":"Ann Rheum Dis."},{"key":"2445_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2161812:1-35","author":"T Bieber","year":"2022","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2022. https:\/\/doi.org\/10.1080\/09546634.2022.2161812:1-35.","journal-title":"J Dermatolog Treat."},{"key":"2445_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac059","author":"B King","year":"2022","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2022. https:\/\/doi.org\/10.1093\/bjd\/ljac059.","journal-title":"Br J Dermatol."},{"key":"2445_CR32","unstructured":"Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975\u20132018, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2018\/, based on November 2020 SEER data submission, posted to the SEER web site, Apr 2021."},{"key":"2445_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/annrheumdis-2018-214261","volume":"78","author":"B Combe","year":"2019","unstructured":"Combe B, Balsa A, Sarzi-Puttini P, et al. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019;78:1135\u20138.","journal-title":"Ann Rheum Dis."},{"key":"2445_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35:476\u201385.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2445_CR35","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399.","journal-title":"N Engl J Med"},{"key":"2445_CR36","doi-asserted-by":"publisher","first-page":"466","DOI":"10.12688\/f1000research.112921.1","volume":"11","author":"R Raj","year":"2022","unstructured":"Raj R, Thomas S, Gorantla V. Accelerated atherosclerosis in rheumatoid arthritis: a systematic review [version 1; peer review: 2 approved, 1 approved with reservations]. F1000Research. 2022;11:466.","journal-title":"F1000Research"},{"key":"2445_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105122","volume":"88","author":"C Ketfi","year":"2021","unstructured":"Ketfi C, Boutigny A, Mohamedi N, et al. Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine. 2021;88: 105122.","journal-title":"Joint Bone Spine"},{"key":"2445_CR38","doi-asserted-by":"crossref","unstructured":"Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2019;78:335\u201341.","DOI":"10.1136\/annrheumdis-2018-214075"},{"key":"2445_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7326\/M15-0919","volume":"164","author":"IM Markusse","year":"2016","unstructured":"Markusse IM, Akdemir G, Dirven L, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment. Ann Intern Med. 2016;164:523\u201331.","journal-title":"Ann Intern Med"},{"key":"2445_CR40","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","volume":"28","author":"I Graham","year":"2007","unstructured":"Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375\u2013414.","journal-title":"Eur Heart J"},{"key":"2445_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","volume":"80","author":"V Molander","year":"2021","unstructured":"Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80:169\u201375.","journal-title":"Ann Rheum Dis"},{"key":"2445_CR42","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81:798\u2013804.","journal-title":"Ann Rheum Dis."},{"key":"2445_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00505-1","author":"CA Salinas","year":"2022","unstructured":"Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2022. https:\/\/doi.org\/10.1007\/s40744-022-00505-1.","journal-title":"Rheumatol Ther"},{"key":"2445_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222824","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-222824.","journal-title":"Ann Rheum Dis."},{"key":"2445_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223050","author":"V Molander","year":"2022","unstructured":"Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-223050.","journal-title":"Ann Rheum Dis"},{"key":"2445_CR46","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1042\u201355.","journal-title":"Arthritis Rheumatol"},{"key":"2445_CR47","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1365-2133.2010.09887.x","volume":"163","author":"A Arana","year":"2010","unstructured":"Arana A, Wentworth CE, Fern\u00e1ndez-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163:1036\u201343.","journal-title":"Br J Dermatol."},{"key":"2445_CR48","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","volume":"156","author":"KE Mansfield","year":"2020","unstructured":"Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156:1086\u201397.","journal-title":"JAMA Dermatol"},{"key":"2445_CR49","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic. Accessed Jan 16, 2023"},{"key":"2445_CR50","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","volume":"168","author":"S Eichinger","year":"2008","unstructured":"Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678\u201383.","journal-title":"Arch Intern Med"},{"key":"2445_CR51","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","volume":"76","author":"EC Keystone","year":"2017","unstructured":"Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76:1853\u201361.","journal-title":"Ann Rheum Dis."},{"key":"2445_CR52","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med"},{"key":"2445_CR53","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333\u201343.","journal-title":"JAMA Dermatol"},{"key":"2445_CR54","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-223356","DOI":"10.1136\/ard-2022-223356"},{"key":"2445_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017;76:17\u201328.","journal-title":"Ann Rheum Dis"},{"key":"2445_CR56","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/rheumatology\/key207","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis\u2014executive summary. Rheumatology (Oxford). 2019;58:220\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"2445_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key023","volume":"57","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57:997\u20131001.","journal-title":"Rheumatology (Oxford)"},{"key":"2445_CR58","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2445_CR59","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. EuroGuiDerm guideline on atopic eczema, version 2.0. October 2022. Available from https:\/\/guidelines.edf.one\/\/guidelines\/living-euroguiderm-guideline-for-the-systemic-treatment-of-atopic-eczema-2 Accessed Nov 28, 2022."},{"key":"2445_CR60","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13979","volume":"33","author":"G Dal Bello","year":"2020","unstructured":"Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther. 2020;33: e13979.","journal-title":"Dermatol Ther."},{"key":"2445_CR61","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","volume":"156","author":"AM Drucker","year":"2020","unstructured":"Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156:659\u201367.","journal-title":"JAMA Dermatol"},{"key":"2445_CR62","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","volume":"11","author":"T Buhl","year":"2021","unstructured":"Buhl T, Rosmarin D, Serra-Baldrich E, et al. Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 phase 3 studies. Dermatol Ther (Heidelb). 2021;11:971\u201382.","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"2445_CR63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242\u201355.","journal-title":"Br J Dermatol."},{"key":"2445_CR64","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s13555-021-00577-x","volume":"11","author":"JP Thyssen","year":"2021","unstructured":"Thyssen JP, Buhl T, Fern\u00e1ndez-Pe\u00f1as P, et al. Baricitinib rapidly improves skin pain resulting in improved quality of life for patients with atopic dermatitis: analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021;11:1599\u2013611.","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"2445_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jaad.2016.02.1234","volume":"75","author":"KP Huang","year":"2016","unstructured":"Huang KP, Joyce CJ, Topaz M, Guo Y, Mostaghimi A. Cardiovascular risk in patients with alopecia areata (AA): a propensity-matched retrospective analysis. J Am Acad Dermatol. 2016;75:151\u20134.","journal-title":"J Am Acad Dermatol."}],"updated-by":[{"DOI":"10.1007\/s12325-025-03244-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02445-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:36:19Z","timestamp":1757100979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02445-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2445"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02445-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-025-03244-1","URL":"https:\/\/doi.org\/10.1007\/s12325-025-03244-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}